SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) insider Anthony J. Recupero sold 5,459 shares of the business’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $24.80, for a total transaction of $135,383.20. Following the sale, the insider now directly owns 222,356 shares of the company’s stock, valued at approximately $5,514,428.80. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
SI-BONE Stock Performance
SIBN opened at $26.22 on Friday. The firm has a 50-day simple moving average of $21.33 and a two-hundred day simple moving average of $17.30. SI-BONE, Inc. has a 52 week low of $11.14 and a 52 week high of $27.24. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.72 and a quick ratio of 6.65.
SI-BONE (NASDAQ:SIBN – Get Rating) last released its quarterly earnings data on Monday, February 27th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.10. SI-BONE had a negative net margin of 47.11% and a negative return on equity of 54.17%. The business had revenue of $31.95 million during the quarter, compared to the consensus estimate of $31.80 million. Equities analysts predict that SI-BONE, Inc. will post -1.44 EPS for the current year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
SIBN has been the subject of a number of recent research reports. Morgan Stanley boosted their price objective on shares of SI-BONE from $18.00 to $22.00 and gave the company an “overweight” rating in a research report on Tuesday, February 28th. Canaccord Genuity Group lifted their target price on shares of SI-BONE from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, February 28th. Truist Financial lifted their target price on shares of SI-BONE from $26.00 to $28.00 in a research note on Tuesday, May 2nd. Cantor Fitzgerald lifted their target price on shares of SI-BONE from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Tuesday, February 28th. Finally, Needham & Company LLC lifted their target price on shares of SI-BONE from $24.00 to $27.00 in a research note on Tuesday, May 2nd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $25.29.
SI-BONE, Inc engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain.
- Get a free copy of the StockNews.com research report on SI-BONE (SIBN)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.